KEY TAKEAWAYS
- The SCOUT-1 trial aimed to evaluate treatment patterns and long-term outcomes, including the use of MTX, in newly diagnosed advanced OC pts.
- The initial data findings highlighted the translation of phase III trial findings into real-world practice for ovarian cancer treatment, warranting further exploration of factors influencing care quality.
The standard treatment for advanced ovarian cancer involves surgery, followed by chemotherapy and maintenance therapy with PARPis or bevacizumab.
Researchers aimed to evaluate treatment patterns and long-term outcomes, including the use of maintenance therapy(MTX), in newly diagnosed advanced ovarian cancer(OC) patients(pts).
About 750 eligible pts who have provided written informed consent, undergone surgery if applicable, tested for BRCA1/2 mutations (either solitary or within HRD-test), and were willing to complete electronic Patient-Reported Outcomes (PROs) and will be enrolled and monitored for up to 7 years.
The study aimed to analyze 3 specific cohorts of PARP inhibitors (PARPi maintenance, bevacizumab maintenance, no maintenance). Interim analysis were planned at 175, 250, and 375 enrolled patients, followed for at least 3 months, to assess cohort distribution safety and obtain initial insights into patient characteristics.
The initial data findings highlighted the translation of phase III trial findings into real-world practice for OC treatment, warranting further exploration of factors influencing care quality.
Source: https://ijgc.bmj.com/content/33/Suppl_3/A274.1
Clinical Trial: https://clinicaltrials.gov/study/NCT04830709
Pietzner K, Braicu EI, Wimberger P, Goldmann J, Kubiak K, De Gregorio N, Radosa JC, Atkas B, Ober A, Brucker C, Meyer-Wilmes P, Melekian B, Sagasser J, Guth D, Schnelzer A, Tchaikovski S, Veldink H, Lampe B, Sehouli J. First interim analysis of the SCOUT-1 Study (NOGGO Ov54, NCT04830709): a non-interventional study to evaluate treatment patterns and long-term outcome in patients with newly diagnosed advanced ovarian cancer.
